Marinus Pharmaceuticals clinical trials

Acquired by Immedica Pharma, Feb 7, 2025 · source ↗

The registry lists 22 studies whose lead sponsor is Marinus Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 1, 2025.

Studies

Recruiting first, then most recently updated. Showing 22 of 22. All Immedica Pharma studies →

• Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related EpilepsyTerminatedNCT05604170Phase 3

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyCompletedNCT05323734Phase 3

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Randomized Therapy In Status EpilepticusCompletedNCT04391569Phase 3

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Open-label Extension to Protocol 1042-0500TerminatedNCT00442104Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)WithdrawnNCT05814523Phase 3

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)WithdrawnNCT05757544Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Ganaxolone Expanded Access Program Compassionate UseNo longer availableNCT04678479

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• A Clinical Trial of Oral Ganaxolone in Women With Postpartum DepressionCompletedNCT03460756Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum DepressionCompletedNCT03228394Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset SeizuresTerminatedNCT02519439Phase 3

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)CompletedNCT03865732Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile SpasmsCompletedNCT00441896Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency DisorderCompletedNCT03572933Phase 3

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Ganaxolone Treatment in Children With Fragile X SyndromeCompletedNCT01725152Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)CompletedNCT04285346Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic EpilepsiesCompletedNCT02358538Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset SeizuresCompletedNCT00465517Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status EpilepticusCompletedNCT03350035Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label ExtensionCompletedNCT01963208Phase 3

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Open-label Extension to Protocol 1042-0600CompletedNCT00512317Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• Ganaxolone in Posttraumatic Stress Disorder (PTSD)CompletedNCT01339689Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma

• A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601CompletedNCT01002820Phase 2

  Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma